Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

637
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
637
Disorders of Leukocytes01:27

Disorders of Leukocytes

1.5K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.5K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

102
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
102
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

1.5K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The gut virome in children undergoing hematopoietic cell transplantation is diverse and a site for viral reactivation.

Bone marrow transplantation·2026
Same author

CPX-351 in High-Risk Relapsed Pediatric Acute Leukemia: Real-World Phase 1 Data Establishing the FDA-Approved Dose.

Pediatric blood & cancer·2026
Same author

Neutrophil extracellular traps, endothelial injury and use of abatacept for graft <i>versus</i> host disease prophylaxis.

Haematologica·2026
Same author

Real world experience using belumosudil for treatment of chronic graft versus host disease in children and young adults.

Bone marrow transplantation·2026
Same author

Integrating palliative care into hematopoietic cell transplantation and cellular therapy training.

Bone marrow transplantation·2025
Same author

Maternal-Fetal Transmission of Diffuse Large B-Cell Lymphoma.

Pediatric blood & cancer·2025

Related Experiment Video

Updated: Nov 17, 2025

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

229

Acute Leukemia in Infants.

Azada Ibrahimova1, Lauren Pommert1,2, Erin H Breese3,4

  • 1Division of Oncology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, MLC 7018, Cincinnati, OH, 45229, USA.

Current Oncology Reports
|February 13, 2021
PubMed
Summary
This summary is machine-generated.

Infant leukemia, a rare and aggressive cancer in children under one, presents unique biological challenges. Current treatments show limited success, necessitating novel therapeutic strategies for better outcomes.

Keywords:
“Acute lymphoblastic leukemia”“Acute myeloid leukemia”“Infant leukemia”“KMT2A rearrangement”

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.0K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.4K

Related Experiment Videos

Last Updated: Nov 17, 2025

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

229
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.0K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.4K

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Molecular Biology

Background:

  • Infant leukemia is a rare, aggressive subgroup of pediatric acute leukemias.
  • Characterized by unique, aggressive biology and high-risk molecular features.
  • Associated with high rates of chemotherapy resistance.

Purpose of the Study:

  • Review clinical presentation of infant leukemia.
  • Discuss underlying molecular biology.
  • Outline current and novel therapeutic approaches.

Main Methods:

  • Review of clinical presentation.
  • Analysis of molecular biology.
  • Evaluation of current and novel treatment strategies.

Main Results:

  • Infant leukemias exhibit high-risk molecular features and chemotherapy resistance.
  • International trials improved understanding but failed to enhance outcomes with chemotherapy intensification.
  • Current regimens cause significant toxicities.

Conclusions:

  • Infants with leukemia remain challenging to treat.
  • Need for collaborative efforts beyond cytotoxic chemotherapy.
  • Incorporate targeted strategies, immunotherapy, and clinical trials for improved outcomes.